Key Points
- Medtronic EVP Harry Kiil sold 1,483 shares for approximately $138,883 at an average price of $93.65, reducing his ownership by 3.4% while retaining 42,186 shares.
- Medtronic’s latest quarter exceeded expectations, with EPS of $1.45 versus the $1.39 consensus and revenue of $9.76 billion, up 13.7% year over year. The stock opened at $92.87 and has a consensus analyst rating of “Moderate Buy” with a $103.92 price target.
- The company declared a quarterly dividend of $0.72 per share, equivalent to $2.88 annually and a 3.1% yield; institutional investors collectively own 82.06% of Medtronic’s stock.
Medtronic PLC (NYSE:MDT - Get Free Report) EVP Harry Kiil sold 1,483 shares of the firm's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president directly owned 42,186 shares in the company, valued at $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Medtronic Trading Up 0.3%
NYSE MDT opened at $92.87 on Friday. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The stock has a 50-day moving average of $88.75 and a 200-day moving average of $84.98. The firm has a market cap of $118.80 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56.
Medtronic (NYSE:MDT - Get Free Report) last issued its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The company had revenue of $9.76 billion during the quarter, compared to analysts' expectations of $9.55 billion. During the same period in the prior year, the business posted $1.26 EPS. Medtronic's quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.97 EPS for the current year.
Medtronic Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic's dividend payout ratio (DPR) is currently 70.94%.
Hedge Funds Weigh In On Medtronic
Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Medtronic by 0.7% in the second quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company's stock worth $8,919,846,000 after buying an additional 838,220 shares during the period. State Street Corp grew its holdings in shares of Medtronic by 2.0% during the 4th quarter. State Street Corp now owns 61,660,158 shares of the medical technology company's stock worth $5,966,780,000 after acquiring an additional 1,199,621 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Medtronic by 2.7% during the 4th quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company's stock worth $5,150,420,000 after acquiring an additional 1,419,730 shares during the period. Capital Research Global Investors raised its position in shares of Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company's stock worth $3,321,101,000 after acquiring an additional 3,880,174 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Medtronic by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company's stock worth $2,665,832,000 after acquiring an additional 231,919 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on MDT. Jefferies Financial Group reissued a "hold" rating and set a $88.00 price target on shares of Medtronic in a research report on Thursday, June 4th. JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $100.00 to $86.00 and set a "neutral" rating for the company in a report on Thursday, June 4th. Needham & Company LLC restated a "buy" rating on shares of Medtronic in a report on Thursday. Piper Sandler reiterated a "neutral" rating on shares of Medtronic in a report on Monday, August 10th. Finally, The Goldman Sachs Group cut their price objective on Medtronic from $84.00 to $83.00 and set a "neutral" rating on the stock in a research report on Thursday, June 4th. Nineteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Medtronic has an average rating of "Moderate Buy" and a consensus target price of $103.92.
View Our Latest Analysis on MDT
Key Medtronic News
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic raised its outlook again as demand for cardiovascular and heart devices continues to climb. Analysts also highlighted market-share gains in electrophysiology and improving momentum across several key franchises, supporting expectations for sustained revenue growth. Medtronic Raises its Outlook Again as Heart Device Demand Keeps Climbing BSX vs. MDT: Which Electrophysiology Stock Is the Better Bet Now?
- Positive Sentiment: The FDA cleared Medtronic’s LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system in the United States. The approval broadens Hugo’s instrument offering and could help Medtronic win additional robotic-surgery procedures and expand the platform’s long-term revenue base. Medtronic Announces FDA Clearance for LigaSure RAS Maryland Instrument
- Positive Sentiment: Coverage of Hugo’s expanding applications presents the surgical-robotics platform as a potential growth engine. Broader clinical use and a larger instrument ecosystem could diversify Medtronic beyond its established device franchises. Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?
- Positive Sentiment: Medtronic’s latest earnings commentary pointed to broad-based growth momentum, complementing its previously reported earnings and revenue beats and year-over-year revenue growth. Medtronic Earnings Call Signals Broad-Based Growth Momentum
- Neutral Sentiment: Medtronic launched a share-exchange offer covering up to approximately 225.4 million newly issued shares as part of its planned diabetes-business spin-off. The transaction may sharpen the company’s strategic focus, although investors will monitor dilution, execution and the final ownership structure. Medtronic Advances Diabetes Spin-Off with Share Exchange
- Neutral Sentiment: Medtronic appointed former ReCor Medical CEO Lara Barghout to lead its Interventional Cardiology Therapies business, adding specialized experience in renal denervation and cardiovascular technology. Recor Medical Former CEO Joins Medtronic
- Negative Sentiment: Executive Vice President Harry Kiil sold 1,483 shares, worth about $139,000. The sale was relatively small and he retained a substantial position, limiting its significance, but insider selling can weigh modestly on sentiment.
About Medtronic
(
Get Free Report)
Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.
The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
